OncoTracker
Private Company
Funding information not available
Overview
ONCOtracker is a privately held, early-stage biotech incubator with a core focus on diagnostics and therapeutic development for multiple myeloma and related B-cell disorders. Its primary assets include a clinically validated serum BCMA (sBCMA) ELISA testing service, a proprietary biobank, and early-stage therapeutic programs involving JAK and gamma secretase inhibitors. The company leverages the deep clinical and research network of its founder, Dr. James Berenson, integrating a specialty clinic, a CRO, and a non-profit research institute to accelerate innovation from bench to bedside.
Technology Platform
Proprietary serum BCMA (sBCMA) ELISA assay for disease monitoring; integrated biobank of long-term clinical myeloma samples; library of patient-derived tumor cell lines for drug evaluation.
Opportunities
Risk Factors
Competitive Landscape
In diagnostics, ONCOtracker competes with central labs and other specialty diagnostic companies developing soluble BCMA and other minimal residual disease (MRD) assays. Its therapeutic concepts (JAK/GSI combinations) compete with numerous large pharmaceutical and biotech firms investing in novel combination regimens for myeloma, though its specific IP may offer a niche angle.